Latest filing published 28 Aug 2026 for Evolent Health, Inc., €282k. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Daniel Joseph McCarthy in Evolent Health, Inc. The record holds 14 filings, for trades running from 21 February 2023 to 26 August 2026.
Market trades split into 1 purchase (€92k) and 3 sales (€422k). Taken together, the sales exceed the purchases by €330k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 9 share grants and 1 option exercise. Since January 2026: no purchases and 1 sale on the market.
The latest filing, published on 28 August 2026, reports an open-market sale of €282k in Evolent Health, Inc. The most recent open-market purchase was published on 10 March 2025, 587 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations